Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use TASIGNA safely and effectively. See full prescribing information for TASIGNA. TASIGNA® (nilotinib) capsules, for oral use Initial U.S. Approval: 2007
Medication labelWhy this: Advisory · dailymed-prescription
Tasigna is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib. Tasigna is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.
- generic_name
- nilotinib
- product_names
- nilotinib
- ndc
- 0078-0526, 0078-0526-87, 0078-0526-51, 0078-0592, 0078-0592-87, 0078-0592-51, 0078-0951, 0078-0951-66
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en